{"id":"W4405048325","doi":"10.1182/blood-2024-200265","title":"Open-Label Phase 1 Study to Evaluate the Safety of SGN-35T in Patients with Relapsed/Refractory CD30-Expressing Lymphoid Malignancies (SGN35T-001; trial in progress)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"Galderma; Eisai; Regeneron Pharmaceuticals; Alexion Pharmaceuticals","keywords":"Medicine; Refractory (planetary science); Open label; Internal medicine; Oncology; Phases of clinical research; Hematologic Neoplasms; Clinical trial; Cancer; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002032249,0.00164486,0.001716865,0.0003068592,0.0004079338,0.001116478,0.0007407731,0.001702515,0.006998322],"category_scores_gemma":[0.0009929097,0.0004304106,0.00118187,0.0003316246,0.001166971,0.001160429,0.0003490587,0.003389435,0.00165861],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001044092,"about_ca_system_score_gemma":0.001658992,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005844251,"about_ca_topic_score_gemma":0.001782002,"domain_scores_codex":[0.999647,0.0001474665,0.00001367546,0.00007302881,0.00003833893,0.00008038518],"domain_scores_gemma":[0.9990438,0.0001029101,0.0002137179,0.00007918211,0.00007347206,0.0004868996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7647873,0.05697696,0.005104702,0.001050744,0.001005786,0.0003416218,0.0003055583,0.002545221,0.04792695,0.0006360417,0.01147908,0.10784],"study_design_scores_gemma":[0.5011103,0.4820006,0.00632613,0.00005742967,0.0002536882,0.0004252002,0.00006055101,0.001423351,0.00289043,0.0006328507,0.004789046,0.00003041417],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9778111,0.003479162,0.001703872,0.001055329,0.0003834496,0.005082339,0.004907893,0.0003522362,0.005224611],"genre_scores_gemma":[0.9689143,0.002525224,0.00426023,0.002391041,0.0003232665,0.005430743,0.008609121,0.00008847053,0.007457543],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006998322,"threshold_uncertainty_score":0.02341175,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0332744518317168,"score_gpt":0.3390484901438522,"score_spread":0.3057740383121354,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}